Answers are grounded in this paper and cite their sources.
Evaluates the shift to continuous manufacturing for tianeptine tablets, indicating successful process adaptation without formulation changes.
Continuous manufacturing has emerged as a promising alternative to conventional batch processing in pharmaceutical production. However, transitioning established batch processes to continuous platforms remains challenging, particularly without altering formulations. Therefore, this study aims to evaluate the feasibility of converting a sustained-release (SR) dual-layer tianeptine sodium tablet from high-shear mixer granulation (HSM) to twin-screw granulation (TSG) while maintaining an identical formulation. A central composite design optimized key process parameters, and their effects on granule and tablet quality attributes were systematically assessed. Compared to HSM, TSG produced granules with broader particle size distributions and slightly reduced flowability; however, it produced tablets with higher hardness and lower friability. Both processes achieved the target dissolution profiles at early, intermediate, and late time points, and the similarity factor (f2 = 89.8) confirmed equivalence. Specifically, the TSG process reduced overall processing time by ~60%. These findings indicate that a quality-by-design-driven adjustment of process parameters enables successful batch-to-continuous conversion without formulation modification, supporting the strategic modernization of SR tablet manufacturing.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: